Form 4 for DGX Quest Diagnostics
Accepted 2023-02-27 00:00:00 ET · period of report 2023-02-23 · accession 0001022079-23-000031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-27 | 2023-02-23 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | A - Grant | $0.00 | +1,919 | 2,921 | +192% | $0 |
| D | 2023-02-27 | 2023-02-23 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | A - Grant | $0.00 | +7,584 | 7,584 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-23 | A | A | 1,919 | $0.00 | 2,921 | D | — | — | (F1) Represents an award of restricted share units. |
| 2 | Derivative | Non-Qualifed Stock Option (right to buy) | 2023-02-23 | A | A | 7,584 | $0.00 | 7,584 | D | $143.33 · — to 2033-02-23 | 7,584 Common Stock | (F2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |